Item 8.01 Other Events.
In connection with its partnership with the National Institute for Viral Disease
Control and Prevention, Chinese Centre for Disease Control and Prevention,
Beijing Youfeng International Consulting Co., Ltd and Beijing Guoxin Haixiang
Equity Investment Partnership, Generex Biotechnology Corporation and its
majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively "Generex")
received $2,000,000 on April 22, 2021, from Beijing Youfeng Biological
Technology Co. LTD ("YouFeng") to provide necessary materials to YouFeng for its
IND submissions to the Chinese National Medical Products Administration (China's
equivalent to the US Food & Drug Administration) to obtain approval in China for
Generex's Ii-Key SARS-CoV-2 coronavirus peptide vaccine.
2
© Edgar Online, source Glimpses